Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China

Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China

Background: The drug therapy of venous thromboembolism (VTE) presents a significant economic burden to the health-care system in low- and middle-income countries. To understand which anticoagulation therapy is most cost-effective for clinical decision-making , the cost-effectiveness of apixaban (API...

Full description

Bibliographic Details
Main Authors:	Ke-Xin Sun, Bin Cui, Shan-Shan Cao, Qi-Xiang Huang, Ru-Yi Xia, Wen-Jun Wang, Jing-Wen Wang, Feng Yu, Yi Ding
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-10-01
Series:	Frontiers in Pharmacology
Subjects:	VTE DOAC CEA = cost-effectiveness analysis China LMWH (low molecular weight heparin)
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2021.716224/full

Similar Items

Venous thromboembolic complications in lymphoma patients
by: Otašević Vladimir, et al.
Published: (2020-01-01)

Occurrence of Venous Thromboembolism in Patients with Lung Cancer  and Its Anticoagulant Therapy
by: Hui DU, et al.
Published: (2018-10-01)

Antithrombotic therapy for secondary prevention of unprovoked venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials
by: Dandan Li, et al.
Published: (2022-12-01)

Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
by: Maha Al-Ghafry, et al.
Published: (2022-10-01)

Direct-Acting Oral Anticoagulant Therapy in Cancer Patients—A Review
by: Tomasz Górnicki, et al.
Published: (2023-05-01)

Non-Vitamin K Antagonist Oral Anticoagulants versus Low Molecular Weight Heparin for Cancer-Related Venous Thromboembolic Events: Individual Patient Data Meta-Analysis
by: Chun En Yau, et al.
Published: (2023-12-01)

Net Clinical Benefit of Direct Oral Anticoagulants in Patients With Cancer and Venous Thromboembolism: A Systematic Review and Trade-Off Analysis
by: Yi-Dan Yan, et al.
Published: (2020-11-01)

Is the use of warfarin becoming obsolete?
by: Tarek Haykal, et al.
Published: (2021-05-01)

Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies
by: Zhi-Yan Liu, et al.
Published: (2022-03-01)

Advances in the Diagnosis of Venous Thromboembolism: A Literature Review
by: Harish Patel, et al.
Published: (2020-06-01)

European expert consensus recommendations on the primary care use of direct oral anticoagulants in patients with venous thromboembolism
by: Carter Patrice, et al.
Published: (2024-03-01)

Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study
by: Alexander T. Cohen, et al.
Published: (2018-05-01)

Clinical epidemiology of venous thromboembolic disease: An institutional registry
by: Mohammed AlSheef, et al.
Published: (2022-07-01)

The Saudi Consensus for the Management of Cancer-Associated Thromboembolism: A Modified Delphi-Based Study
by: Mohammed Alsheef, et al.
Published: (2023-01-01)

The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases
by: Domenico Acanfora, et al.
Published: (2021-09-01)

Heparin‐induced hyperkalemia, can LMWH cause hyperkalemia? A systematic review
by: Gedion Yilma Amdetsion, et al.
Published: (2023-11-01)

The Antineoplastic Effect of Heparin on Colorectal Cancer: A Review of the Literature
by: Emmanuel Giannas, et al.
Published: (2023-11-01)

CLINICAL PICTURE, DIAGNOSIS AND PREVENTION OF VENOUS THROMBOEMBOLIC COMPLICATIONS DURING PREGNANCY
by: S. V. Akinshina, et al.
Published: (2016-06-01)

Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer
by: Alice Labianca, et al.
Published: (2020-07-01)

Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients
by: Song AB, et al.
Published: (2019-06-01)

A Cross-sectional Study of the Assessment of Venous Thromboembolism Risk and Use of Anticoagulant Thromboprophylaxis
by: Emile Abimana, et al.
Published: (2022-03-01)

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
by: Javier Trujillo‐Santos, et al.
Published: (2022-05-01)

LMWHs have additional advantage over unfractionated heparin: no volume load
by: GP Koracevic
Published: (2009-10-01)

Thrombosis risk and in vitro fertilization
by: E. Grandone
Published: (2022-03-01)

Preventing Venous Thromboembolism in Ambulatory Patients with Cancer: A Narrative Review
by: Anne Rossel, et al.
Published: (2020-03-01)

COVID-19 and Venous Thromboembolism: From Pathological Mechanisms to Clinical Management
by: Xianghui Zhou, et al.
Published: (2021-12-01)

Prevention of Venous Thromboembolism in 2020 and Beyond
by: Matthew Nicholson, et al.
Published: (2020-08-01)

Venous Thromboembolism in Pregnancy: Challenges and Solutions
by: Varrias D, et al.
Published: (2023-07-01)

Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis
by: Anthony Chan, et al.
Published: (2018-11-01)

Retrospective Evaluation of Intravenous Enoxaparin Administration in Feline Arterial Thromboembolism
by: Athanasia Mitropoulou, et al.
Published: (2022-08-01)

New Insights in Thrombin Inhibition Structure–Activity Relationships by Characterization of Octadecasaccharides from Low Molecular Weight Heparin
by: Pierre A. J. Mourier, et al.
Published: (2017-03-01)

Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications
by: Marco Heestermans, et al.
Published: (2022-10-01)

Prostate Cancer History and Total Hip Arthroplasty: A Matched Cohort Analysis Investigating Venous Thromboembolism and Anticoagulation
by: Keir Johnson, BS, et al.
Published: (2022-10-01)

Sulfated non-anticoagulant heparin blocks Th2-induced asthma by modulating the IL-4/signal transducer and activator of transcription 6/Janus kinase 1 pathway
by: Mohamed A. Ghonim, et al.
Published: (2018-09-01)

Does the choice of chemoprophylaxis affect the prevention of deep vein thrombosis in lumbar fusion surgery? A systematic review of the literature
by: Sathish Muthu, et al.
Published: (2023-01-01)

Influence of the duration of hospital length of stay on frequency of prophylaxis and risk for venous thromboembolism among patients hospitalized for acute medical illnesses in the USA
by: Alpesh Amin, et al.
Published: (2019-01-01)

SECONDARY PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) WITH LOW DOSE APIXABAN OR RIVAROXABAN: RESULTS FROM A PATIENT POPULATION WITH MORE THAN 2 YEARS OF MEDIAN FOLLOW-UP
by: Alessandro Laganà, et al.
Published: (2024-02-01)

Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients
by: Pasquale Paolisso, et al.
Published: (2020-08-01)

Incidence and influence factors of venous thromboembolism in traumatic rib fracture patient: a multicenter study
by: Dongsheng Zhang, et al.
Published: (2024-02-01)

Extracellular vesicles in ovarian cancer - A role in venous thromboembolism?
by: Mark P. Ward, PhD
Published: (2021-05-01)